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We describe the use of 2-deoxy-D-[6-W]glucose to follow simultaneously, by i3C NMR, both transport and phosporyla- 
tion to its 6-phosphate form, in MCF-7 breast cancer cells in vitro and in vivo in subcutaneous tumors in nude mice. 
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1. INTRODUCTION 
The synthetic glucose analog, 2-deoxy-D-glucose 
(2DG), competes with glucose for carrier-mediated 
transport into cells where it is phosphorylated by 
hexokinase to a stable end product, 2-deoxy-D- 
glucose 6-phosphate (2DG6P). Radioisotopes of 
2DG and its derivative 2-fluoro-2-deoxy-D-glucose 
(FDG) have been used extensively for monitoring 
regional glucose utilization in vivo. Simultaneous 
measurement of rates of glucose consumption in 
various components of rat brain using [14C]2DG 
and quantitative autoradiography was developed 
by Sokoloff and co-workers [l]. With the advent 
of positron emission tomography (PET), this con- 
cept was extended to studies examining cerebral 
function in patients by monitoring [‘*F]FDG and 
[“C]2DG [2,3]. Monitoring 2DG utilization by 
PET is currently being developed for clinical 
diagnosis of tumors [4] and has provided a means 
of tumor grading [5] and differentiating between 
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radiation necrosis and recurrent tumors [6]. These 
techniques measure a differential accumulation of 
2DG6P, simulating glucose utilization, but do not 
differentiate between transport and phospho- 
rylation. 
Here, we describe a method for simultaneously 
monitoring both processes by 13C magnetic 
resonance spectroscopy (MRS). The metabolism of 
2DG has previously been monitored in vivo by 31P, 
19F, and 13C MRS. The phosphorylation of 2DG 
was observed in a suspension of ascites tumor cells 
[7], and in situ in rat brain by 31P MRS [8], 
although the 2DG6P signal was poorly resolved 
from the phosphomonoester signals. We en- 
countered the same problem in monitoring the 
metabolism of 2DG in tumor tissue in vivo by 31P 
MRS. 19F MRS has been used to follow the brain 
metabolism of FDG beyond the hexokinase reac- 
tion [9]. The 19F chemical shifts of FDG and FDG 
6-phosphate are so close in solution [lo] that they 
could not be resolved in vivo. In a preliminary 
report, the metabolism of [13C]2DG was followed 
in rat brain [l 11. We have demonstrated that both 
2DG and 2DG6P can be monitored in tumor tissue 
subcutaneously implanted in mice and in a suspen- 
sion of the same tumor cells derived from culture. 
The signal from 2DG enriched with 13C in the C6 
position (the site of phosphorylation) is clearly 
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resolved from the phosphorylated product, 




2. MATERIALS AND METHODS 
2.1. Materials 
2-Deoxy-D-[6-‘“Clglucose was kindly furnished as a gift from 
the NIH-sponsored Stable Isotope Resource at Los Alamos Na- 
tional Laboratory and by Dr Joseph J.H. Ackerman, 
Washington University, St. Louis, MO. 2DG was purchased 
from Sigma (St. Louis, MO). The cell growth medium was im- 
proved minimal Eagle’s medium (IMEM, NIH Media Unit) 
with 5% fetal calf serum and penicillin-streptomycin 
(100 U/ml, 10 mg/l) and modified to contain 4 mM D-glucose. 
a-ATP 
I 
I T-ATP /I 
PRE-TREATMENT 
2.2. Cultured cells 
Wild-type MCF-7 human breast cancer cells were grown in 
monolayers in the described growth media under a 5% COZ en- 
vironment. Cells were harvested using 0.5% trypsin, 0.2% 
EDTA in Dirk’s saline (Gibco), centrifuged at 4°C at 730 x g 
for 10 min and washed three times in the growth media. Cell 
suspensions for in vitro MRS were prepared as follows. Follow- 
ing centrifugation, the cell pellet (0.4 ml, approx. 8 x lo7 cells) 
was transferred to a 10 ml NMR tube and diluted to 1.8 ml with 
cold growth media and maintained at 4°C. Cold DzO (0.1 ml) 
and 1.65 mg [6-‘“C]2DG in 0.1 ml growth media were added to 
make a final concentration of 5 mM 2DG in 2.0 ml suspension 
of cells. Oxygen was continuously bubbled in the bottom of the 
tube to oxygenate the cells and to prevent settling. During the 
5 min tuning and shimming period, the suspension was allowed 
to warm to 22”C, which initiated the uptake of 2DG. 
2.3. Tumor-bearing mice 
Athymic nude mice which had been implanted subcutaneous- 
ly with MCF-7 cells were obtained from Frederick Cancer 
Research Facility (Frederick, MD). Mice were sedated for MRS 
studies by i.p. injection of chloral hydrate in 0.9% saline at a 
dose of 430 mg/kg. 
Fig.1. In vivo ‘rP spectra of human breast tumor (MCF-7) 
subcutaneously implanted in a nude mouse (fasted for 18 h); 
pretreatment and 2 h following i.p. administration of 2 g/kg 
dose of 2DG. Peaks identified as: PE, phosphoethanolamine; 
PC, phosphocholine; Pi, inorganic phosphate; PCr, 
phosphocreatine; DPDE, diphosphodiester; DG6P, 2-deoxy- 
glucose Cphosphate. Each spectrum was collected for 60 scans 
at a 5 s repetition time, using 20 ps pulse width (70”) and 20 Hz 
line broadening. 
2.4. Spectroscopy 
3’P spectra at 162 MHz and 13C spectra at 100 MHz with 
proton decoupling were recorded on a Varian XL-400 NMR 
spectrometer. All spectra of solid tumors in vivo were collected 
using a custom-designed probe as in [12]. In vitro spectra of 
suspended cells were collected using a Varian lO-mm high- 
resolution probe at 22°C. The spectral parameters are listed in 
the figure legends. 
3. RESULTS AND DISCUSSION 
4.6 ppm. As shown in an earlier study [8], 2DG6P 
was not resolved from the PME region containing 
phosphoethanolamine (PE) and phosphocholine 
(PC). During post-treatment the signal intensity of 
the PME region increased with a concurrent 
decline in Pi. This increasing peak was observed 
and assigned in extracts to 2DG6P. 
In vivo 31P spectra of an MCF-7 tumor sub- In order to follow the uptake of 2DG and its 
cutaneously implanted in an athymic mouse are phosphorylation “C MRS was used to monitor 
shown in fig.1. The mouse was fasted for 18 h [6-r3C]2DG. Since phosphorylation occurs at posi- 
prior to administration of 2 g/kg 2DG i.p. Except tion 6, the chemical shifts of the carbon in this 
for the reduction in Pi, the uptake and position are affected the most. The 13C chemical 
phosphorylation of 2DG had little effect on the shifts of carbon 6 in 2DG are 63.82 ppm (cu- 
observed phosphates. 2DG6P resonates in the anomer) and 63.88 ppm (,&anomer) vs 65.88 and 
phosphomonoester (PME) region of the spectra at 66.01 ppm for the (Y- and ,&anomers at pH 7.1 
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following phosphorylation (note chemical shifts 
are pH-dependent). 
The phosphorylation of 13C-enriched 2DG was 
first demonstrated in vitro using a suspension of 
intact MCF-7 cells. 13C spectra were collected 
every 4.3 min following the addition of 1.65 mg 
[6-r3C]2DG to 2.0 ml of cell suspension containing 
I I 
66.0 63.9 ppm 
Fig.2. In vitro ‘H-decoupled 13C spectra of a suspension of 
MCF-7 cells in a Varian 10 mm high-resolution probe at 22°C. 
Spectra are shown at various times following the addition of 
1.65 mg [6-‘“C]2DG to 8 x 10’ cells in 2.0 ml media. Peaks are 
identified as (Y- and &anomers of [6-‘“C]2DG and 2DG6P. 
Each spectrum was collected for 200 scans at 1.4 s repetition 
time using 15 ,us pulse width (66”) and 7 Hz line broadening. 
8 x 10’ cells. Since the course of the process was 
sufficiently shorter in duration, and r3C material 
very scarce, it was not considered necessary to per- 
fuse these cells [13]. As shown in fig.2,2DG6P was 
present following the addition of 2DG and 
resonances of its cy- and ,&anomers were clearly 
resolved from those of 2DG. The time course for 
production of 2DG6P is shown in fig.3. The rate 
of decrease in 2DG is somewhat greater than the 
rate of increase in 2DG6P. A linear net loss in total 
13C label was observed. This could be attributed to 
loss of [r3C]2DG, since this signal would not fit 
well to an exponential decay, but ran parallel to the 
sum of the total signal at long times, and was fitted 
well with an exponential plus a linear decay with 
the same slope derived from the sum. By contrast, 
the signal for 2DG6P was fitted well by an ex- 
ponential increase. The rates derived from the fits 
were corrected for the amount of protein in the cell 
preparation, and gave values of 8.3 x 10e4 and 6.5 
x 10V4 mM/min per mg protein for 2DG and 
2DG6P, respectively. The net loss of 2DG at long 
times could be attributed to 2DG6P being further 
metabolized [9,14], and/or gradual damage to cell 
integrity, which is shown by the loss of most of the 
ATP in the “P NMR spectra after 4 h. 
A proton-decoupled natural-abundance 13C 
spectrum of an MCF-7 tumor subcutaneously im- 
planted in an athymic mouse is shown in fig.4a. 
The spectrum is characterized by a large envelope 
of methyl and methylene carbons (14-46 ppm) 
with a peak at 32 ppm, trimethylamine groups of 
2 c -I 
0 1’ I 
0 50 100 150 200 
Time (min) 
Fig.3. Time course of utilization of 2DG and production of 
2DG6P by MCF-7 cells in vitro. Data from signal intensities of 
‘“C spectra described in fig.2. 
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b 
Fig.4. In vivo ‘H-decoupled ‘“C spectra of MCF-7 cells 
subcutaneously implanted in a nude mouse (fasted for 18 h); 
pretreatment (control) and following i.p. administration of 
1 g/kg dose of [6-r3C]2DG. Peaks identified in b as 2DG6P 
(66 ppm) and 2DG (64 ppm). 
phosphatidylcholine at 54.8 ppm, olefinic carbons 
at 130 and 132 ppm, and carbonyl carbons at 
173 ppm [12]. The fasted mouse (18 h) was in- 
jected i.p. with a 1 g/kg dose of [6-“C]2DG. Both 
2DG and 2DG6P appeared in the first spectrum 
(1 l-32 min). These peaks are clearly resolved 
from each other and the background (natural- 
abundance spectrum) as shown in fig.4b. The time 
course for the appearance of 2DG and 2DG6P in 
the tumor in vivo is shown in fig.5. This represents 
a composite of several processes including uptake 
and elimination of 2DG, phosphorylation of 2DG, 
and elimination of 2DG6P. The maximum signal 
intensity for 2DG occurs at 60 min and for 2DG6P 
at 110 min. 
It has been shown that the multidrug-resistant 
(mdr) line of MCF-7 tumor cells, known as AdrR, 
has a 3-fold higher rate of glycolysis vs wild-type 
cells [ 151. It has been suggested that 2DG may be 
used as a metabolic inhibitor of tumor growth 
[ 16- 181. In order to evaluate the effectiveness of a 
combination of 2DG and adriamycin as 
therapeutic agent against the mdr cell line, it is 
necessary to be able to compare the rates of uptake 
and phosphorylation, and we are currently per- 
forming these studies. The present results 
demonstrate the efficacy of using 13C-labelled 
rim0 (mitt) 
Fig.5 Time course of utilization of 2DG and production of 
2DG6P by an MCF-7 tumor in vivo. Data from signal 
intensities of 13C spectra described in fig.4. 
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sugar analogs, particularly 2DG that is labelled at 
the position of phosphorylation, in order to follow 
a metabolic process in vitro and in vivo. 
Acknowledgements: We wish to thank Dr James Fee of the Los 
Alamos National Laboratory and Dr Joseph J.H. Ackerman 







Sokoloff, L., Reivich, M., Kennedy, C., Des Rosiers, 
M.H., Patlak, C.S., Pettigrew, K.D., Sakurada, 0. and 
Shinohara, M. (1977) J. Neurochem. 28, 897-916. 
Reivich, M., Kuhl, D., Wolf, A., Greenberg, J., Phelps, 
M., Ido, T., Casella, V., Fowler, J., Hoffman,,E., Alavi, 
A., Som, P. and Sokoloff, L. (1979) Circ. Res. 44, 
127-137. 
Phelps, M.E., Mazziotta, J.C. and Huang, S.C. (1982) J. 
Cereb. Blood Flow Metab. 2, 113-162. 
Beaney, R.P. (1984) Seminars Nucl. Med. 14, 324-341. 
Di Cbiro, G., DeLaPaz, R.L., Brooks, R.A., Sokoloff, 
L., Kornblith, P.L., Smith, B.H., Patronas, N. J., Kufta, 
C.V., Kessler, R.M., Johnston, G.S., Manning, R.G. and 
Wolf, A.P. (1982) Neurology 32, 1323-1329. 
[61 Patronas, N.J., Di Chiro, G., Brooks, R.A., DeLaPaz, 
R.L., Kornblith, P.L., Smith, B.H., Rizzoli, H.V., 
Kessler, R.M., Manning, R.G., Channing, M., Wolf, 













Navon, G., Ogawa, S., Shulman, R.G. and Yamane, T. 
(1977) Proc. Natl. Acad. Sci. USA 74, 87-91. 
Deuel, R.K., Yue, G.M., Sherman, W.R., Schicker, D.J. 
and Ackerman, J.J.H. (1985) Science 228, 1329-1331. 
Nakada, T., Kwee, I.L. and Conboy, CC. (1986) J. 
Neurochem. 46, 198-201. 
Nakada, T., Kwee, I.L., Rao, G.A. and Conboy, C.C. 
(1985) Biochem. Arch. 1, 163-166. 
Kotyk, J.J., Rust, R.S., Deuel, R.K. and Ackerman, 
J.J.H. (1987) Proc. Sot. Magn. Reson. Med. Sixth Annu. 
Meet., ~445. 
Lyon, R.C., Tschudin, R.G., Daly, P.F. and Cohen, J.S. 
(1988) Magn. Reson. Med. 6, 1-14. 
Lyon, R.C., Faustino, P.J. and Cohen, J.S. (1986) Magn. 
Reson. Med. 3, 636-672. 
Renner, E.D., Plageman, P.G.W. and Bernlohr, R.W. 
(1972) J. Biol. Chem. 247, 5765-5776. 
Lyon, R.C., Cohen, J.S., Faustino, P.J., Megnin, F. and 
Myers, C.E. (1988) Cancer Res. 48, 870-877. 
Woodward, G.E. and Hudson, M.T. (1954) Cancer Res. 
14, 599-605. 
Jain, V.K., Kalia, U.K., Sharma, R., Maharajan, V. and 
Menon, M. (1985) Int. J. Radiat. Oncol. Biol. Phys. 11, 
943-950. 
1181 Halanka, M. (1974) Biochim. Biophys. Acta 355, 77-104. 
90 
